150 years of Friedreich Ataxia: From its discovery to therapy

Journal of Neurochemistry

Volumn 126, Issue SUPPL.1, 2013, Pages 1-3

  Schulz, Jörg B ^a   Pandolfo, Massimo ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; DEFERIPRONE; DNA; ERYTHROPOIETIN; FRATAXIN; GUANINE; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; IRON SULFUR PROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

CHROMOSOME MARKER; DNA MODIFICATION; EDITORIAL; EUROPE; FRIEDREICH ATAXIA; FXN GENE; GENE; GEOGRAPHIC DISTRIBUTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; R1B GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRINUCLEOTIDE REPEAT;

CLINICAL TRIALS AS TOPIC; FRIEDREICH ATAXIA; GERMANY; HISTORY, 19TH CENTURY; HUMANS; IRON-BINDING PROTEINS;

EID: 84880376563     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12327     Document Type: Editorial

References (18)

1. Bürk K., Schulz S. R., and, Schulz J. B., (2013) Monitoring progression in Friedreich Ataxia (FRDA): the use of clinical scales. J. Neurochem. 126 (Suppl. 1), 118-124.
2. Campuzano V., Montermini L., Molto M. D., et al,. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.
3. Cnop M., Mulder H., and, Igoillo-Esteve M., (2013) Diabetes in Friedreich Ataxia. J. Neurochem. 126 (Suppl. 1), 94-102.
4. Friedreich N., (1863a) Ueber degenerative Atrophie der spinalen Hinterstränge. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 26, 391-419.
5. Friedreich N., (1863b) Ueber degenerative Atrophie der spinalen Hinterstränge. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 26, 433-459.
6. Friedreich N., (1863c) Ueber degenerative Atrophie der spinalen Hinterstränge. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 27, 1-26.
7. González-Cabo P., and, Palau F., (2013) Mitochondrial pathophysiology in Friedreich's ataxia. J. Neurochem. 126 (Suppl. 1), 53-64.
8. Gottesfeld J. M., Rusche J. R., and, Pandolfo M., (2013) Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J. Neurochem. 126 (Suppl. 1), 147-154.
9. Koeppen A., (2013) Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord. J. Neurochem. 126 (Suppl. 1), 4-10.
10. Mariotti C., Nachbauer W., Panzeri M., Poewe W., Taroni F., and, Boesch S., (2013) Erythropoietin in Friedreich ataxia. J. Neurochem. 126 (Suppl. 1), 80-87.
11. Pandolfo M., and, Hausmann L., (2013) Deferiprone for the treatment of Friedreich's ataxia. J. Neurochem. 126 (Suppl. 1), 142-146.
12. Parkinson M. H., Boesch S., Nachbauer W., Mariotti C., and, Giunti P., (2013 a) Clinical features of Friedreich's Ataxia: classical and atypical phenotypes. J. Neurochem. 126 (Suppl. 1), 103-117.
13. 10 and idebenone use in Friedreich's Ataxia. J. Neurochem. 126 (Suppl. 1), 125-141.
14. Pastore A., and, Puccio H., (2013) Frataxin: a protein in search for a function. J. Neurochem. 126 (Suppl. 1), 43-52.
15. Perdomini M., Hick A., Puccio H., and, Pook M. A., (2013) Animal and cellular models of Friedreich ataxia. J. Neurochem. 126 (Suppl. 1), 65-79.
16. Vankan P., (2013) Prevalence gradients of Friedreich's Ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J. Neurochem. 126 (Suppl. 1), 11-20.
17. Weidemann F., Störk S., Liu D., Hu K., Herrmann S., Ertl G., and, Niemann M., (2013) Cardiomyopathy of Friedreich Ataxia. J. Neurochem. 126 (Suppl. 1), 88-93.
18. Yandim C., Natisvili T., and, Festenstein R., (2013) Gene regulation and epigenetics in Friedreich's ataxia. J. Neurochem. 126 (Suppl. 1), 21-42.